The
global medical
aesthetics market is projected to reach $19,419.7 million by 2023, growing
at a CAGR of 12.2% during 2017 - 2023.
Global medical aesthetics market
worth $8,629.9 million in 2016
According
to the study, the global medical aesthetics market is likely to grow from $8.6 billion
in 2016 to $19.4 billion by 2023. Advancement in laser technology, growing awareness among consumers, and
health benefits of medical aesthetics procedures have been driving the global medical
aesthetics market. The market is further expected to gain revenue due to shift in
the preference from surgical to non-surgical procedures. There has been a
significant growth in non-surgical medical spa procedures in the recent years,
resulting from better technologies, such as intense pulsed light and advanced
laser based aesthetics equipment.
Access Report Overview: https://www.psmarketresearch.com/market-analysis/medical-aesthetics-market
Insights
on market segments
As
per the findings of research, injectables held the largest share in the global
market in 2016, primarily due to high sales of botulinum toxin. Topicals, the
second largest medical aesthetics product segment, witnessed the highest growth
during 2013 – 2016. The highest growth of topicals is attributed to their
ability to treat several skin conditions without any usage of uncomfortable
procedures. Beauty clinics and centers was the largest end user of the global
medical aesthetics market in 2016., followed by spas and salons.
North America stands as
the largest medical aesthetics market
Browse Report Sample at: https://www.psmarketresearch.com/market-analysis/medical-aesthetics-market/report-sample
Key players in the medical
aesthetics market actively seeking acquisitions
The
medical aesthetics market has witnessed number of mergers and acquisitions and
strategic alliances recently. In December 2016, Allergan
Plc. acquired LifeCell, a medicine company of Acelity L.P. Inc., for a cash
consideration of $2.9 billion. The acquisition is expected to combine
LifeCell’s business of regenerative medicines with Allergan’s medical
aesthetics business. Allergan aims to strengthen its presence in regenerative
medicine business with this acquisition. In
April 2016, the company also acquired Topokine Therapeutics, a private company
developing topical medicines for fat reduction, for a total consideration of
$85.0 million. Topokine Therapeutics’ XAF5 is in late-stage development for the
treatment of steatoblepharon.
No comments:
Post a Comment